<DOC>
	<DOCNO>NCT00687739</DOCNO>
	<brief_summary>The purpose study evaluate potential mechanism estradiol deficiency accelerate fat gain abdominal fat accumulation woman .</brief_summary>
	<brief_title>Prevention Obesity Women Via Estradiol Regulation</brief_title>
	<detailed_description>Many factor contribute current epidemic obesity . Although estrogen status commonly recognize determinant obesity risk woman , strong evidence large randomize controlled trial estradiol ( E2 ) -based hormone therapy ( HT ) reduces weight gain 40 % postmenopausal woman . Importantly , also strong evidence E2 reduce abdominal fat accumulation , fundamental component Metabolic Syndrome . Some study suggest risk HT outweigh benefit woman . However , negate importance learn mechanism E2 influence energy balance fat patterning . This study use gonadotropin release hormone ( GnRH ) analog therapy determine effect chronic ( 5-month ) sex hormone suppression rest energy expenditure ( REE ) , alter hypothalamic-pituitary-adrenal ( HPA ) axis activity , fat gain . It hypothesize REE reduce response chronic sex hormone suppression , promote fat gain . It also hypothesize stress-induced hypothalamic-pituitary-adrenal ( HPA ) axis activity amplify sex hormone suppression ; alter HPA axis activity lead cortisol excess cause abdominal fat accumulation . Finally , hypothesize E2 add-back therapy lessen response . Participants randomize half woman treatment arm participate exercise training program , consist progressive resistance exercise prevent decline fat-free mass ( FFM ) increase fat mass observe young woman response GnRH analog therapy .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Healthy premenopausal woman , age 18 49 year Regular menses ( miss cycle previous year ; cycle length 2535 day ) Positive luteinizing hormone test midluteal serum progesterone great 3 ng/mL Nonsmokers Willing receive study intervention Physically able willing randomize participate supervise resistance exercise train program Already perform highintensity resistance exercise train 1 day per week On diabetes medication Use hormonal contraception past 3 month On oral inhaled glucocorticoid Positive pregnancy test Intention become pregnant start hormonal contraceptive therapy period study Lactation Hypersensitivity extrinsic peptide hormone , mannitol , Gonadotropinreleasing hormone ( GnRH ) , leuprolide acetate , benzyl alcohol ( vehicle injection leuprolide acetate ) , transdermal patch Score great 16 Center Epidemiologic Studies Depression Scale Beck Depression InventoryII score great 18 , clinician recommendation exclude Severe osteopenia osteoporosis ( proximal femur lumbar spine score &lt; 2.0 ) BMI great 40 kg/m2 , weight change Â± 2 kg last 6 month , weightreduced 5 kg maximal body weight Abnormal vaginal bleeding History breast cancer estrogendependent neoplasms History venous thromboembolic event Moderate severe renal impairment ( creatinine clearance &lt; 50 mL/min CockcroftGault ) Chronic hepatobiliary disease , define liver function test ( AST , ALT , alkaline phosphatase , total bilirubin ) great 1.5 time upper limit normal Thyroid dysfunction , define ultra sensitive TSH le 0.5 great 5.0 mU/L Uncontrolled hypertension , define rest BP great 150/90 mmHg Cardiovascular disease , include indicator ischemic heart disease serious arrhythmias rest grade exercise test ; followup diagnostic testing rule cardiovascular disease cardiologist allow Orthopedic problem would interfere participation exercise program</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hormone therapy</keyword>
	<keyword>obesity</keyword>
	<keyword>postmenopause</keyword>
	<keyword>disease /disorder proneness /risk</keyword>
	<keyword>insulin sensitivity /resistance</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>woman 's health</keyword>
</DOC>